Abstracts tagged "dermatomyositis"

Abstract Number: 1007 • ACR Convergence 2024
Demographic, Social, and Disease Factors Associated with Interstitial Lung Disease and Disease-Related Death in Dermatomyositis
Connor Buechler, Lindsey Wanberg, Nawang Singhe, Cody Rasner, Joseph McGrath, Ziou Jiang, Karen Baker-James and David Pearson, University of Minnesota, Minneapolis, MN
Background/Purpose: Dermatomyositis (DM) is associated with significant morbidity and mortality due to disease-related progressive interstitial lung disease (ILD) and malignancy. However, little is known about…
Abstract Number: 1260 • ACR Convergence 2024
Toward a Treat-to-target Strategy in Juvenile Dermatomyositis: Seeking for Suitable Targets and Optimal Timing of Their Achievement
Silvia Rosina¹, Ana Isabel Rebollo-Giménez², Chiara Campone³, Valentina Natoli², Alessandro Consolaro², Francesca Bovis³ and Angelo Ravelli⁴, ¹IRCCS Istituto Giannina Gaslini, Genoa, Italy, ²IRCCS Istituto Giannina Gaslini, Genova, Italy, ³Università degli Studi di Genova, Genova, Italy, ⁴IRCCS Giannina Gaslini, Genoa, Italy
Background/Purpose: The management of juvenile dermatomyositis (JDM) is not standardized and no widely embraced therapeutic protocols are available. Furthermore, the optimal therapeutic targets as well…
Abstract Number: 1844 • ACR Convergence 2024
Manufacturing of IMPT-514, a CD19/CD20 Bispecific CAR T Cell Product Candidate as a Potential Treatment of Patients with Autoimmune Diseases
Ethan BenDavid, Nathanael Joshua Bangayan, Orit Foord, Michael Weist, Melanie Munguia, Jessica Reyes and Jiajia Cui, ImmPACT Bio, West Hills, CA
Background/Purpose: Immunotherapies targeting antigens expressed on B cells are currently being explored as treatments for autoimmune disorders like antineutrophil cytoplasmic antibody (ANCA)-associated vasculitis (AAV), idiopathic…
Abstract Number: 1051 • ACR Convergence 2024
Healthcare Costs and Resource Utilization Associated with Long-term Medium-to-high Dose Oral Corticosteroid Use in Patients with Dermatomyositis or Polymyositis
Daniel Labson¹, Qian Cai², Concetta Crivera³ and Federico Zazzetti⁴, ¹Janssen Global Services, LLC, a Johnson & Johnson Company, Global Market Access RWE, Raritan, NJ, ²Janssen Global Services, LLC, a Johnson & Johnson Company, Global Market Access RWE, Titusville, NJ, ³Janssen Global Services, LLC, a Johnson & Johnson Company, Immunology Market Access, Horsham, PA, ⁴Johnson & Johnson Innovative Medicine, Horsham, PA, PA
Background/Purpose: Dermatomyositis (DM) and polymyositis (PM) are rare autoimmune conditions primarily characterized by muscle weakness and inflammation. Real-world evidence on economic outcomes of patients with…
Abstract Number: 1261 • ACR Convergence 2024
Association of Muscle Biopsies and Functional Recovery Trajectories in Children with Juvenile Dermatomyositis
Shannon O'Connor¹, Ilaria Maccora², Megan Quinlan-Waters¹, hermine brunner³, sheila Angeles-Han⁴, grant schulert¹ and leah kottyan¹, ¹Cincinnati Children's Hospital Medical Center, Cincinnati, OH, ²?PhD student, in the Area of Drugs and Innovative Treatments, NeuroFARBA Department, University of Florence. Meyer Children's Hospital, Florence Italy, Firenze, Florence, Italy, ³Cincinnati Children's Hospital Medical Center, University of Cincinnati College of Medicine, Cincinnati, OH, ⁴Cincinnati Children's Hospital, Cincinnati, OH
Background/Purpose: Juvenile dermatomyositis (JDM) is an idiopathic inflammatory myopathy characterized by proximal muscle weakness, a distinct rash, and an increased risk of calcinosis, with long-term…
Abstract Number: 2001 • ACR Convergence 2024
Complications and Treatment Use Associated with Long-term Oral Corticosteroid Therapy Among Patients with Dermatomyositis or Polymyositis
Rohit Aggarwal¹, Qian Cai², Daniel Labson³, Concetta Crivera⁴ and Federico Zazzetti⁵, ¹Division of Rheumatology and Clinical Immunology, University of Pittsburgh, Pittsburgh, PA, USA, Pittsburgh, PA, ²Janssen Global Services, LLC, a Johnson & Johnson Company, Global Market Access RWE, Titusville, NJ, ³Janssen Global Services, LLC, a Johnson & Johnson Company, Global Market Access RWE, Raritan, NJ, ⁴Janssen Global Services, LLC, a Johnson & Johnson Company, Immunology Market Access, Horsham, PA, ⁵Johnson & Johnson Innovative Medicine, Horsham, PA, PA
Background/Purpose: Idiopathic Inflammatory Myopathies (IIM) are a group of rare systemic autoimmune conditions mainly characterized by muscle weakness, rash and involvement of various organs. Dermatomyositis…
Abstract Number: 0247 • ACR Convergence 2024
Enhanced Immunogenicity of the Recombinant Herpes Zoster Vaccine After One-Week of Mycophenolate Mofetil Discontinuation in Patients with Autoimmune Rheumatic Diseases: Interim Results from a Prospective Randomized Phase 4 Study
Sandra Pasoto¹, Isabele Antonelli¹, Ana Cristina Medeiros-Ribeiro², Nadia Aikawa³, Leonard Kupa¹, Eduardo Borba¹, Luciana Seguro⁴, Emily Figueiredo Neves Yuki¹, ANA PAULA ASSAD¹, Carla Saad⁴, Andrea Shimabuco⁴, Andrea Negrini¹, Julia Medeiros¹, Talita Ribeiro¹, Samuel Shinjo⁴, Percival Sampaio-Barros⁴, Danieli Andrade⁵, Fernando Souza⁴, Renata Miossi⁴, Clovis Silva⁶ and Eloisa Bonfa¹, ¹Rheumatology Division, Hospital das Clinicas HCFMUSP, Faculdade de Medicina, Universidade de Sao Paulo, Sao Paulo, SP, Brazil, São Paulo, SP, Brazil, ²Rheumatology Division, Hospital das Clinicas HCFMUSP, Faculdade de Medicina, Universidade de Sao Paulo, Sao Jose Dos Campos, Brazil, ³Rheumatology Division and Pediatric Rheumatology Unit, Hospital das Clinicas HCFMUSP, Faculdade de Medicina, Universidade de São Paulo, São Paulo, SP, Brazil, ⁴Rheumatology Division, Hospital das Clinicas HCFMUSP, Faculdade de Medicina, Universidade de Sao Paulo, São Paulo, SP, Brazil, ⁵University of São Paulo, São Paulo, SP, Brazil, ⁶Rheumatology Division and Pediatric Rheumatology Unit, Instituto da Criança e do Adolescente, Hospital das Clinicas HCFMUSP, Faculdade de Medicina, Universidade de Sao Paulo, São Paulo, SP, Brazil
Background/Purpose: Recently, it was demonstrated that temporarily halting mycophenolate mofetil (MMF) for 1-week post-COVID-19 vaccination in systemic lupus erythematosus (SLE) patients improved humoral response, without…
Abstract Number: 1111 • ACR Convergence 2024
Impact of Scleroderma, Antiphospholipid Syndrome, Behçet’s Disease, and Dermatomyositis on Mortality Among Hospitalized Patients with Pulmonary Embolism
Kessiena Aomreore, Lincoln Medical Center, New york, NY
Background/Purpose: Autoimmune diseases are associated with a high prevalence of pulmonary embolism due to the inflammation-induced hyper coagulable state.This study aimed to analyze trends in…
Abstract Number: 1264 • ACR Convergence 2024
Improving Mental Health Care for Youth with Juvenile Dermatomyositis Through Integration of Mental Health Screening into Pediatric Rheumatology Clinic
Emily Datyner, Lisa Buckley, Brittany Nelson and Alaina Davis, Monroe Carell Jr. Children's Hospital at Vanderbilt, Nashville, TN
Background/Purpose: The negative impact of juvenile dermatomyositis (JDM) on emotional health is well-recognized. Barriers to appropriate mental health treatment include limited availability of providers and…
Abstract Number: 2060 • ACR Convergence 2024
Clustering Analysis of Immune Cell Subtypes and Clinical Phenotypes in Idiopathic Inflammatory Myopathy
xiaoyan xing¹, Yuhui Li² and Jing He³, ¹Department of Rheumatology and Immunology and Beijing Key Laboratory for Rheumatism and Immune Diagnosis (BZ0135), Peking University People’s Hospital, Beijing, China, Beijing, China, ²Peking University, BeiJing, China, ³Rheumatology, Beijing, China
Background/Purpose: Immune cell profiling plays a pivotal role in the pathogenesis of idiopathic inflammatory myopathy (IIM). Characterizing immune cell subtypes, such as CD4+ T cells,…
Abstract Number: 0325 • ACR Convergence 2024
The Impact of Polymyositis and Dermatomyositis in Patients Hospitalized with Inflammatory Bowel Disease: A Nationwide Inpatient Database Analysis
Pitchaporn Yingchoncharoen¹, Nattanicha Chaisrimaneepan², Jerapas Thongpiya¹, Pojsakorn Danpanichkul¹ and Yanint Raksadawan³, ¹Texas Tech Health Sciences Center, Lubbock, TX, ²Texas Tech University Health Sciences Center, Lubbock, TX, ³Weiss Memorial Hospital, Chicago, IL
Background/Purpose: Polymyositis and dermatomyositis (PM/DM) are subtypes of idiopathic inflammatory myopathies, belonging to the spectrum of polygenic autoimmune diseases Inflammatory bowel disease (IBD), encompassing ulcerative…
Abstract Number: 1140 • ACR Convergence 2024
Pulmonary Hypertension in Hospitalized Patients with Dermatomyositis & Polymyositis: A Nationwide Cohort Analysis
Saman Tanveer¹, Daksh Ahluwalia¹, Fatima Tanveer², Abdullah Saeed³, Almurtada Razok⁴ and Faria Sami⁵, ¹John H. Stroger Jr. Hospital of Cook County, Chicago, IL, ²CMH Lahore Medical and Dental College, Lahore, Pakistan, ³CMH Lahore Medical and Dental College, Lahore, Punjab, Pakistan, ⁴John H Stroger Jr Hospital of Cook County, Chicago, IL, ⁵University of Alabama, Chicago, IL
Background/Purpose: Dermatomyositis (DM) and polymyositis (PM) are idiopathic inflammatory myopathies characterized by muscles inflammation, proximal muscle weakness and extramuscular manifestations. A particularly challenging extramuscular manifestation…
Abstract Number: 1265 • ACR Convergence 2024
Approach to Janus Kinase Inhibition for Juvenile Dermatomyositis Among Childhood Arthritis and Rheumatology Research Alliance (CARRA) and Paediatric Rheumatology European Society (PReS) Providers
Emily Datyner¹, Rebecca Nicolai², Silvia Rosina³, Angela Hamilton⁴, Kaveh Ardalan⁵, Brigitte Bader-Meunier⁶, Amanda Brown⁷, Raquel Campanilho-Marques⁸, Marc Jansen⁹, Susan Kim¹⁰, Bianca Lang¹¹, Liza McCann¹², Helga Sanner¹³, Meredyth Wilkinson¹⁴, Belina Yi¹⁵, Hanna Kim¹⁶, Matthew Sherman¹⁷, Stacey Tarvin⁴ and Charalampia Papadopoulou¹⁸, and the CARRA and PReS investigators, ¹Monroe Carell Jr. Children's Hospital at Vanderbilt, Nashville, TN, ²Division of Rheumatology, IRCCS Ospedale Pediatrico Bambino Gesù, Rome, Italy, ³IRCCS Istituto Giannina Gaslini, Genoa, Italy, ⁴Indiana University School of Medicine, Indianapolis, IN, ⁵Duke University School of Medicine, Durham, NC, ⁶Necker Hospital, Assistance Publique Hopitaux de Paris, Paris, France, ⁷University of Arkansas for Medical Sciences, Little Rock, AR, ⁸Lisbon Academic Medical Centre, Lisboa, Portugal, ⁹University Medical Center Utrecht, Utrecht, Netherlands, ¹⁰University of California, San Francisco, CA, ¹¹Dalhousie University and IWK Health, Halifax, NS, Canada, ¹²Alder Hey Children's NHS Foundation Trust, Liverpool, England, United Kingdom, ¹³Oslo University Hospital, Oslo, Norway, ¹⁴Great Ormond Street Institute of Child Health, London, United Kingdom, ¹⁵Johns Hopkins University School of Medicine, Baltimore, MD, ¹⁶National Institute of Arthritis Musculoskeletal and Skin Diseases, National Institutes of Health, Bethesda, MD, ¹⁷DAIT/NIAID/NIH, Washington, DC, ¹⁸Great Ormond Street Hospital for Children, NHS Foundation Trust, London, United Kingdom
Background/Purpose: Janus kinase inhibitors (JAKi) have been proposed as a treatment for idiopathic inflammatory myopathies to target increased interferon signaling. Predominantly retrospective reports have demonstrated…
Abstract Number: 2062 • ACR Convergence 2024
Performance of the Patient Self-Assessment Tools for Cutaneous Dermatomyositis: Patient CDASI and Rash Mapping
Nantakarn Pongtarakulpanit¹, Tanya Chandra¹, shiri keret², Eugenia Gkiaouraki³, Vladimir Liarski¹, Dana Ascherman³, Siamak Mogahadam¹, Chester Oddis¹ and Rohit Aggarwal⁴, ¹Division of Rheumatology and Clinical Immunology, University of Pittsburgh, Pittsburgh, PA, ²Rheumatology unit, Bnai-Zion medical center and the faculty of Medicine, Technion - Israel Institute of Technology, Haifa, Israel., Atlit, Israel, ³Division of Rheumatology and Clinical Immunology, University of Pittsburgh Medical Center, Pittsburgh, PA, ⁴Division of Rheumatology and Clinical Immunology, University of Pittsburgh, Pittsburgh, PA, USA, Pittsburgh, PA
Background/Purpose: Cutaneous Dermatomyositis Disease Area and Severity Index (CDASI) is a current standard for evaluating rashes in Dermatomyositis (DM). However, there is increasing emphasis on…
Abstract Number: 0328 • ACR Convergence 2024
IFI27 Is Differentially Upregulated in Anti-MDA5 Dermatomyositis and Correlates with the Presence of Interstitial Lung Disease
Melissa Leeolou¹, Lorinda Chung², Kavita Sarin³ and david fiorentino⁴, ¹Stanford University School of Medicine, Redwood City, CA, ²Stanford University, Woodside, CA, ³Department of Dermatology, Stanford University School of Medicine, Redwood City, CA, ⁴Department of Dermatology, Stanford University School of Medicine, Stanford, CA, Palo Alto, CA
Background/Purpose: Type I interferon (IFN) plays a role in the pathogenesis of dermatomyositis (DM) and correlates with measures of disease activity. Melanoma differentiation-associated gene 5…

All abstracts accepted to ACR Convergence are under media embargo once the ACR has notified presenters of their abstract’s acceptance. They may be presented at other meetings or published as manuscripts after this time but should not be discussed in non-scholarly venues or outlets. The following embargo policies are strictly enforced by the ACR.

Accepted abstracts are made available to the public online in advance of the meeting and are published in a special online supplement of our scientific journal, Arthritis & Rheumatology. Information contained in those abstracts may not be released until the abstracts appear online. In an exception to the media embargo, academic institutions, private organizations, and companies with products whose value may be influenced by information contained in an abstract may issue a press release to coincide with the availability of an ACR abstract on the ACR website. However, the ACR continues to require that information that goes beyond that contained in the abstract (e.g., discussion of the abstract done as part of editorial news coverage) is under media embargo until 10:00 AM ET on November 14, 2024. Journalists with access to embargoed information cannot release articles or editorial news coverage before this time. Editorial news coverage is considered original articles/videos developed by employed journalists to report facts, commentary, and subject matter expert quotes in a narrative form using a variety of sources (e.g., research, announcements, press releases, events, etc.).

Violation of this policy may result in the abstract being withdrawn from the meeting and other measures deemed appropriate. Authors are responsible for notifying colleagues, institutions, communications firms, and all other stakeholders related to the development or promotion of the abstract about this policy. If you have questions about the ACR abstract embargo policy, please contact ACR abstracts staff at [email protected].